BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38594506)

  • 1. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions.
    Boelaars K; Rodriguez E; Huinen ZR; Liu C; Wang D; Springer BO; Olesek K; Goossens-Kruijssen L; van Ee T; Lindijer D; Tak W; de Haas A; Wehry L; Nugteren-Boogaard JP; Mikula A; de Winde CM; Mebius RE; Tuveson DA; Giovannetti E; Bijlsma MF; Wuhrer M; van Vliet SJ; van Kooyk Y
    Commun Biol; 2024 Apr; 7(1):430. PubMed ID: 38594506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9.
    Rodriguez E; Boelaars K; Brown K; Eveline Li RJ; Kruijssen L; Bruijns SCM; van Ee T; Schetters STT; Crommentuijn MHW; van der Horst JC; van Grieken NCT; van Vliet SJ; Kazemier G; Giovannetti E; Garcia-Vallejo JJ; van Kooyk Y
    Nat Commun; 2021 Feb; 12(1):1270. PubMed ID: 33627655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma.
    Zhang A; Qian Y; Ye Z; Chen H; Xie H; Zhou L; Shen Y; Zheng S
    Cancer Med; 2017 Feb; 6(2):463-470. PubMed ID: 28097809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.
    Egan H; Treacy O; Lynch K; Leonard NA; O'Malley G; Reidy E; O'Neill A; Corry SM; De Veirman K; Vanderkerken K; Egan LJ; Ritter T; Hogan AM; Redmond K; Peng L; Che J; Gatlin W; Jayaraman P; Sheehan M; Canney A; Hynes SO; Kerr EM; Dunne PD; O'Dwyer ME; Ryan AE
    Cell Rep; 2023 May; 42(5):112475. PubMed ID: 37167967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
    Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
    Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
    Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells.
    Wiley SZ; Sriram K; Liang W; Chang SE; French R; McCann T; Sicklick J; Nishihara H; Lowy AM; Insel PA
    FASEB J; 2018 Mar; 32(3):1170-1183. PubMed ID: 29092903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
    Yu Y; Schuck K; Friess H; Kong B
    Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
    Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
    J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
    Stouten I; van Montfoort N; Hawinkels LJAC
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.
    McAndrews KM; Chen Y; Darpolor JK; Zheng X; Yang S; Carstens JL; Li B; Wang H; Miyake T; Correa de Sampaio P; Kirtley ML; Natale M; Wu CC; Sugimoto H; LeBleu VS; Kalluri R
    Cancer Discov; 2022 Jun; 12(6):1580-1597. PubMed ID: 35348629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
    Boelaars K; van Kooyk Y
    Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of tumor cell sialylation in pancreatic cancer progression.
    Marciel MP; Haldar B; Hwang J; Bhalerao N; Bellis SL
    Adv Cancer Res; 2023; 157():123-155. PubMed ID: 36725107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
    Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM
    Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
    van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
    Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-associated fibroblasts reprogram cysteine metabolism to increase tumor resistance to ferroptosis in pancreatic cancer.
    Zhu Y; Fang S; Fan B; Xu K; Xu L; Wang L; Zhu L; Chen C; Wu R; Ni J; Wang J
    Theranostics; 2024; 14(4):1683-1700. PubMed ID: 38389839
    [No Abstract]   [Full Text] [Related]  

  • 19. Decoding Metabolic Symbiosis between Pancreatic Cancer Cells and Cancer-Associated Fibroblasts Using Cultured Tumor Microenvironment.
    Nihashi Y; Song X; Yamamoto M; Setoyama D; Kida YS
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma.
    Neuzillet C; Nicolle R; Raffenne J; Tijeras-Raballand A; Brunel A; Astorgues-Xerri L; Vacher S; Arbateraz F; Fanjul M; Hilmi M; Samain R; Klein C; Perraud A; Rebours V; Mathonnet M; Bièche I; Kocher H; Cros J; Bousquet C
    J Pathol; 2022 Dec; 258(4):408-425. PubMed ID: 36102377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.